IPG-1094 is under clinical development by Immunophage Biotech and currently in Phase I for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase I drugs for Multiple Myeloma (Kahler Disease) have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IPG-1094’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IPG-1094 is under development for the treatment of systemic lupus erythematosus, psoriasis, multiple sclerosis, multiple myeloma, colon cancer, and advanced solid tumors including brain tumor, triple-negative breast cancer, Head and neck cancer and non-small cell lung cancer. It is administered through oral route. The drug candidates act by targeting macrophage migration inhibitory factor (MIF).
Immunophage Biotech overview
Immunophage Biotech (Immunophage) is an innovative drug research and development company. Immunophage is headquartered in Shanghai, China.
For a complete picture of IPG-1094’s drug-specific PTSR and LoA scores, buy the report here.